Document Detail

Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
MedLine Citation:
PMID:  16834827     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: A high prevalence of associated metabolic cardiovascular risk factors is often observed among hypertensive subjects. The aim of the present study was to assess the effects of 1-2 mg/day of rilmenidine, a centrally acting antihypertensive agent with selectivity for I(1) imidazoline receptors, vs. 2.5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome. RESEARCH DESIGN AND METHODS: In this 6-month multicentre, comparative, double-blind, parallel group study, the primary objective was to assess the effects of the treatments on blood pressure (BP); the secondary endpoints were to assess glucose and lipid metabolism, in addition to clinical and biological tolerability. In non-responder patients, dose adjustment was possible from the first month and adding a diuretic from the third month. RESULTS: Of an intention-to-treat population of 93 patients, 84 per protocol patients completed the study: 42 in the rilmenidine group and 42 in the isradipine group. BP decreased significantly (p < 0.001) and similarly in both groups (systolic blood pressure, SBP: -16.0 +/- 17.2 mmHg and -15.0 +/- 13.0 mmHg, and diastolic blood pressure, DBP: -9.0 +/- 9.4 mmHg and -9.0 +/- 8.7 mmHg with rilmenidine and isradipine, respectively). Normalisation (DBP < 90 mmHg and SBP < 140 mmHg) and response (normalisation or decrease in SBP >or= 20 mmHg or decrease in DBP >or= 10 mmHg) rates were respectively 57% and 72% with rilmenidine and 64% and 79% with isradipine (NS between groups). The effects of the treatments on both glucose and lipid metabolism were comparable: no significant difference from baseline was observed on the main parameters including insulin sensitivity indexes. The two treatments appeared to be well tolerated throughout the study, with no serious adverse reaction reported in the rilmenidine group and one serious adverse event in the isradipine group (a perimalleolar oedema), leading to withdrawal from the study for the affected patient. CONCLUSION: This study suggests that in hypertensive patients with metabolic disorders, rilmenidine is an effective antihypertensive treatment, comparable to isradipine, with metabolic neutrality and a good tolerance profile.
Jirí Widimský; Jana Sirotiaková
Related Documents :
15258427 - Relationship between somatotype and blood pressure in a group of institutionalized vene...
15295727 - Comparison of etomidate and midazolam for prehospital rapid-sequence intubation.
11239257 - Effectiveness and safety of prehospital urapidil for hypertensive emergencies.
12115017 - A randomized, double-blind, controlled trial of vitamin c in the management of hyperten...
3738407 - Circannual rhythms of systolic and diastolic blood pressure in relation to plasma aldos...
25005227 - Scaffolding builds to reduce blood pressure.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current medical research and opinion     Volume:  22     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-07-12     Completed Date:  2006-08-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  1287-94     Citation Subset:  IM    
Third Internal Department, Hospital of the First Medical Faculty, Prague, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Blood Glucose / analysis
Blood Pressure / drug effects
Double-Blind Method
Drug Tolerance
Hypertension / complications*,  drug therapy*
Insulin / blood
Isradipine / therapeutic use*
Lipids / blood
Metabolic Syndrome X / complications*,  drug therapy*
Middle Aged
Oxazoles / therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Blood Glucose; 0/Lipids; 0/Oxazoles; 11061-68-0/Insulin; 54187-04-1/rilmenidine; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-lab...
Next Document:  Disease control in asthmatic children seen in private practice in Switzerland.